Technical Analysis for BCYC - Bicycle Therapeutics plc
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 22.52 | -0.66% | -0.15 |
Earnings due: May 2
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
20 DMA Resistance | Bearish | -0.66% | |
20 DMA Resistance | Bearish | -0.71% | |
50 DMA Resistance | Bearish | -0.22% | |
Fell Below 20 DMA | Bearish | -0.22% | |
Fell Below 50 DMA | Bearish | -3.97% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -3.97% | |
20 DMA Support | Bullish | -3.97% | |
Inside Day | Range Contraction | -3.97% |
Alert | Time |
---|---|
10 DMA Support | about 16 hours ago |
Possible NR7 | about 16 hours ago |
60 Minute Opening Range Breakout | about 18 hours ago |
10 DMA Resistance | about 19 hours ago |
Fell Below Previous Day's Low | about 20 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
Bicycle Therapeutics plc Description
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Disease Immunology Oncology Tumor Ophthalmology Hematology Immune Checkpoint Cancer Research Search Technology
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 28.9 |
52 Week Low | 12.54 |
Average Volume | 409,270 |
200-Day Moving Average | 20.32 |
50-Day Moving Average | 23.89 |
20-Day Moving Average | 22.97 |
10-Day Moving Average | 22.63 |
Average True Range | 1.20 |
RSI (14) | 45.65 |
ADX | 18.48 |
+DI | 17.85 |
-DI | 18.89 |
Chandelier Exit (Long, 3 ATRs) | 22.35 |
Chandelier Exit (Short, 3 ATRs) | 25.20 |
Upper Bollinger Bands | 24.62 |
Lower Bollinger Band | 21.31 |
Percent B (%b) | 0.37 |
BandWidth | 14.43 |
MACD Line | -0.27 |
MACD Signal Line | -0.24 |
MACD Histogram | -0.028 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 23.57 | ||||
Resistance 3 (R3) | 23.51 | 23.11 | 23.39 | ||
Resistance 2 (R2) | 23.11 | 22.84 | 23.13 | 23.33 | |
Resistance 1 (R1) | 22.81 | 22.67 | 22.61 | 22.87 | 23.28 |
Pivot Point | 22.41 | 22.41 | 22.31 | 22.44 | 22.41 |
Support 1 (S1) | 22.12 | 22.14 | 21.91 | 22.17 | 21.76 |
Support 2 (S2) | 21.71 | 21.98 | 21.74 | 21.71 | |
Support 3 (S3) | 21.42 | 21.71 | 21.65 | ||
Support 4 (S4) | 21.47 |